When your quarterly report reads like a weather forecast, you know the monsoon’s now on the audit committee. 🌧️ Dhanuka blamed both excess and missing rains — a first for corporate versatility. Yet, even the clouds couldn’t dampen their optimism: Dahej is brewing new molecules, and Nippon Soda’s partnership brings some imported chemistry to desi soil. As the Bhagavad Gita reminds us — “You have the right to perform your duty, but not to the fruits of action.” Read on — because the fruits (and margins) get juicier later.
2. At a Glance
Revenue down 9% – Even the rain gods took a commission this time.
PAT ₹93.9 Cr (↓20%) – Profits washed away faster than pests in heavy rain.
Royalty income ₹4.5 Cr – Courtesy of Bayer, but no fireworks yet.
Stock flat – Investors also stuck in kharif-rabi confusion.
3. Management’s Key Commentary
M.K. Dhanuka: “Uneven rainfall impacted agrochemical demand.” (Translation: Nature cut 9% off our topline, no Excel error here.)
Harsh Dhanuka: “Trial production of Difenoconazole has begun at Dahej.” (Translation: The lab is cooking, just don’t ask when the revenue gets served.)
Rahul Dhanuka: “Farmers didn’t shift to generics, they just didn’t spray anything.” (Translation: Even weeds got a monsoon break 😏.)
Vinod Bansal (CFO): “Dahej sales ₹22 Cr, with a nominal loss of ₹46 lakh.” (Translation: ‘Nominal loss’ = CFO’s polite word for bleeding cash.)
Harsh Dhanuka: “Bayer revenue will be lower this year; royalties up.” (Translation: We’re still getting rent, not the house yet.)
Rahul Dhanuka: “We are exploring backward integration and acquisition opportunities.” (Translation: Wallet’s full, ideas pending approval.)
Management: “Digital outreach growing on Instagram and YouTube.” (Translation: Farmers are swiping reels before they spray fields.)
4. Numbers Decoded
Metric
Q2 FY26 Value
YoY Change
One-Line Analysis
Revenue from Ops
₹598.3 Cr
↓9%
Monsoon rewrote sales script.
EBITDA
₹136.7 Cr
↓14%
Weather and weak herbicides hit margins.
PAT
₹93.9 Cr
↓20%
Profit washed off, still decent control.
Dahej Sales
₹22 Cr
NA
Small but symbolic start.
Royalty Income (Bayer)
₹4.5 Cr
Flat
Bayer blessings continue modestly.
Herbicide Share
9%
↓Significant
Hero turned villain this quarter.
Bio-stimulant Sales Impact
-₹20 Cr
New
Regulation shock, but future tailwind.
5. Analyst Questions
Q: What’s happening at Dahej? A: Trial run of Difenoconazole on track. Profit? Maybe FY27. (Translation: “Trial” = loss rehearsal.)
